OnKure is discovering and developing a portfolio of highly mutant-selective PI3Kα inhibitors with the goal of improving efficacy and safety by fully inhibiting the mutant oncogene while sparing the wild-type enzyme in normal tissues. The company is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program.
Cyborg Score Rationale
The stock has a market capitalization of $36.72 million with a PE ratio of -0.57. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating, with a consensus price target of $32.00. The company is pre-revenue and clinical-stage, facing significant execution risk typical of early biotech companies.
Top Insights
PI3KαH1047R is the most common mutation in the PI3K gene, being found in 15% of breast cancer and 4% of cancers overall.
The company began trading on the Nasdaq Global Market on October 7, 2024 under the ticker symbol OKUR.
Current market cap is $36.72 million, down significantly from recent highs.
90.98% of the stock is owned by institutional investors.